HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.
Seeking Alpha

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Please reach out to your Barclays representative to schedule a one-on-one meeting. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research ...

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - ...
Seeking Alpha

Alpha Tau to Participate in December Investor Conferences

Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your Piper Sandler and Sidoti representatives to schedule. About Alpha Tau Medical Ltd. Founded in 2016, ...

Alpha Tau price target raised to $12 from $9 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on ...
Nasdaq

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT®- - Ad-hoc analyses of pancreatic cancer ...
Business Insider

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma ...

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, ...
Business Insider

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data ...
Nasdaq

Alpha Tau Medical Achieves MDSAP Certification for Jerusalem Manufacturing Facility

Alpha Tau Medical Ltd. announced that it has achieved Medical Device Single Audit Program (MDSAP) certification for its manufacturing facility in Jerusalem, which is a key step in ensuring quality, ...
Morningstar

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive ...
MarketWatch

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

The MarketWatch News Department was not involved in the creation of this content. - Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular ...